

Michael Schweitz, MD
President

Michael Stevens, MD
Vice President

Mark Box, MD
Secretary

Gregory Schimizzi, MD
Treasurer

Jacob Aelion, MD
Director

Aaron Broadwell, MD
Director

Gary R. Feldman, MD
Director

Madelaine Feldman, MD
Director

Philippe Saxe, MD
Director

Joshua Stolow, MD
Director

Robert Sylvester, MD
Director

Two Woodfield Lake
1100 E Woodfield Road, Suite 350
Schaumburg, IL 60173-5116
Phone: (847) 517-7225 | (847) 517-7229
Email: csro@wjweiser.com | Website: www.csro.info

March 5, 2015

Colorado House Health, Insurance & Environment Committee
Colorado State Capitol
200 E. Colfax Ave.
Denver, CO 80203

Re: Support of SB 15-071 (McCann) – Pharm Substitute Interchangeable Biological Drug

Dear Members of the House Health, Insurance & Environment Committee:

The Coalition of State Rheumatology Organizations (CSRO) is a national organization composed of 30 state and regional professional rheumatology societies formed to ensure excellence and access to the highest quality care for patients with rheumatologic and musculoskeletal disease.

Rheumatologists are especially aware of the dramatic, life-changing clinical improvements that biological products have on some of the most disabling conditions that affect Americans. Biological products available for the treatment of rheumatoid arthritis and other autoimmune diseases have a significant impact on improving our patients' quality of life, preventing disability, and lowering mortality.

As your Committee considers SB 15-071 (McCann), CSRO wishes to convey its support for the premise of the legislation.

We would also like to emphasize the critical importance communication to a prescriber has on patient safety in Colorado. As currently written, SB 15-071 calls for a communication period to be "Within a reasonable time." Requiring prior communication before a prescription is filled, or a specific communication period shortly after, offers physicians a safer and more consistent window to understand and counter any adverse effects of medications. We ask that the communication provision be amended to define a set time period.

CSRO recognizes that follow-on biologics and biosimilars are a natural evolution of medications and as the FDA is expected to approve the first biosimilar drugs this year, we welcome this important update to existing law in Colorado. At the same time, we must insist that patient safety remain the first concern and request all legislation on biosimilars allow physicians to quickly know what medicine their patient receives.

Sincerely,



Michael Schweitz, MD
President
Coalition of State Rheumatology Organizations